Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Pharm Biotechnol ; 12(10): 1707-14, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21466443

ABSTRACT

The development of new therapeutic approaches to the treatment of painful neuropathies requires a better understanding of the mechanisms that underlie chronic pain syndromes. There is increasing evidence that immune competent cells such as microglia contribute to the development of chronic pain states. Chemokines play a pivotal role in mediating neuronal-microglial communication which leads to increased nociception. Fractalkine (FKN) is structurally unique amongst the family of chemokines and their receptors and expressed both in the central nervous system and peripheral nerves, as well as in endothelial cells and lymphocytes. Signalling via the CX3CR1 receptor, FKN is able to mediate critical physiological functions necessary for immune regulation. In its soluble forms FKN mediates chemotaxis of immune cells whilst membrane bound FKN acts as an adhesion molecule mediating leukocyte capture and infiltration. As FKN/CX3CR1 is such a key signalling pair for homeostatic functions it is not surprising that it is implicated in a large number of diseases in which imbalance of the immune system is implied. Here we review the evidence that FKN/CX3CR1 mediates neuron-microglial communication in chronic pain states and is therefore key in the development of neuropathic pain. In addition, the contribution of FKN/CX3CR1 signalling to the pathogenesis and progression of two chronic inflammatory conditions, atherosclerosis and rheumatoid arthritis, are discussed.


Subject(s)
Chemokine CX3CL1/metabolism , Chronic Pain/metabolism , Inflammation/metabolism , Receptors, Chemokine/metabolism , Animals , CX3C Chemokine Receptor 1 , Humans , Signal Transduction
2.
Arthritis Rheum ; 63(3): 819-29, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21360511

ABSTRACT

OBJECTIVE: To investigate the involvement of transient receptor potential ankyrin 1 (TRPA1) in inflammatory hyperalgesia mediated by tumor necrosis factor α(TNFα) and joint inflammation. METHODS: Mechanical hyperalgesia was assessed in CD1 mice, mice lacking functional TRP vanilloid 1 (TRPV1-/-) or TRPA1 (TRPA1-/-), or respective wildtype (WT) mice. An automated von Frey system was used, following unilateral intraplantar injection of TNFα or intraarticular injection of Freund's complete adjuvant (CFA). Knee swelling and histologic changes were determined in mice treated with intraarticular injections of CFA. RESULTS: TNFα induced cyclooxygenase-independent bilateral mechanical hyperalgesia in CD1 mice. The selective TRPV1 receptor antagonist SB-366791 had no effect on mechanical hyperalgesia when it was coinjected with TNFα, but intrathecally administered SB- 366791 attenuated bilateral hyperalgesia, indicating the central but not peripheral involvement of TRPV1 receptors. A decrease in pain sensitivity was also observed in TRPV1-/- mice. Intraplantar coadministration of the TRPA1 receptor antagonist AP-18 with TNFα inhibited bilateral hyperalgesia. Intrathecal treatment with AP-18 also reduced TNFα-induced hyperalgesia. CFA-induced mechanical hyperalgesia in CD1 mice was attenuated by AP-18 (administered by intraarticular injection 22 hours after the administration of CFA). Furthermore, intraarticular CFA­induced ipsilateral mechanical hyperalgesia was maintained for 3 weeks in TRPA1 WT mice. In contrast, TRPA1-/- mice exhibited mechanical hyperalgesia for only 24 hours after receiving CFA. CONCLUSION: Evidence suggests that endogenous activation of peripheral TRPA1 receptors plays a critical role in the development of TNFα-induced mechanical hyperalgesia and in sustaining the mechanical hyperalgesia observed after intraaarticular injection of CFA. These results suggest that blockade of TRPA1 receptors may be beneficial in reducing the chronic pain associated with arthritis.


Subject(s)
Arthritis, Experimental/immunology , Hyperalgesia/immunology , TRPV Cation Channels/immunology , Transient Receptor Potential Channels/immunology , Tumor Necrosis Factor-alpha/immunology , Adjuvants, Immunologic/pharmacology , Anilides/pharmacology , Animals , Arthralgia/chemically induced , Arthralgia/immunology , Arthritis, Experimental/chemically induced , Cinnamates/pharmacology , Disease Models, Animal , Female , Freund's Adjuvant/pharmacology , Hyperalgesia/chemically induced , Injections, Intra-Articular , Injections, Spinal , Male , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Knockout , TRPA1 Cation Channel , TRPV Cation Channels/antagonists & inhibitors , TRPV Cation Channels/genetics , Transient Receptor Potential Channels/antagonists & inhibitors , Transient Receptor Potential Channels/genetics , Tumor Necrosis Factor-alpha/pharmacology
3.
J Neurochem ; 114(4): 1143-57, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20524966

ABSTRACT

The chemokine fractalkine (FKN) is a critical mediator of spinal neuronal-microglial communication in chronic pain. Mature FKN is enzymatically cleaved from neuronal membranes and activation of its receptor, CX3CR1, which is expressed by microglia, induces phosphorylation of p38 MAPK. We used CX3CR1 knockout (KO) mice to examine pain behaviour in the absence of FKN signalling. Naive CX3CR1 KO mice had normal responses to acute noxious stimuli. However, KO mice showed deficits in inflammatory and neuropathic nociceptive responses. After intraplantar zymosan, KO mice did not display thermal hyperalgesia, whereas mechanical allodynia developed fully. In the partial sciatic nerve ligation model of neuropathic pain, both mechanical allodynia and thermal hyperalgesia were less severe in KO mice than in wild-types (WT). Dorsal horn Iba1 immunostaining and phosphorylation of p38 MAPK increased after injury in WT controls but not in KO animals. In WT mice, inflammation and nerve injury increased spinal cord CX3CR1 and FKN expression. FKN protein was also increased in KO mice following inflammation but not after neuropathy, suggesting the FKN/CX3CR1 system is differently affected in the two pain models. Loss of FKN/CX3CR1 neuroimmune communication attenuates hyperalgesia and allodynia in a modality-dependent fashion highlighting the complex nature of microglial response in pathological pain models.


Subject(s)
Hyperalgesia/genetics , Hyperalgesia/metabolism , Inflammation Mediators/physiology , Microglia/metabolism , Peripheral Nervous System Diseases/genetics , Peripheral Nervous System Diseases/metabolism , Receptors, Chemokine/metabolism , Spinal Cord/metabolism , Animals , CX3C Chemokine Receptor 1 , Calcium-Binding Proteins/metabolism , Chemokine CX3CL1/metabolism , Disease Models, Animal , Female , Hyperalgesia/physiopathology , Inflammation Mediators/antagonists & inhibitors , Male , Mice , Mice, Knockout , Mice, Transgenic , Microfilament Proteins , Microglia/pathology , Peripheral Nervous System Diseases/physiopathology , Posterior Horn Cells/metabolism , Posterior Horn Cells/physiopathology , Receptors, Chemokine/genetics , Sciatic Neuropathy/genetics , Sciatic Neuropathy/metabolism , Sciatic Neuropathy/physiopathology , Spinal Cord/physiopathology , Up-Regulation/physiology , p38 Mitogen-Activated Protein Kinases/metabolism
4.
J Neurosci ; 30(2): 573-82, 2010 Jan 13.
Article in English | MEDLINE | ID: mdl-20071520

ABSTRACT

The cytokine interleukin-1beta (IL-1beta) released by spinal microglia in enhanced response states contributes significantly to neuronal mechanisms of chronic pain. Here we examine the involvement of the purinergic P2X7 receptor in the release of IL-1beta following activation of Toll-like receptor-4 (TLR4) in the dorsal horn, which is associated with nociceptive behavior and microglial activation. We observed that lipopolysaccharide (LPS)-induced release of IL-1beta was prevented by pharmacological inhibition of the P2X7 receptor with A-438079, and was absent in spinal cord slices taken from P2X7 knock-out mice. Application of ATP did not evoke release of IL-1beta from the dorsal horn unless preceded by an LPS priming stimulus, and this release was dependent on P2X7 receptor activation. Extensive phosphorylation of p38 MAPK in microglial cells in the dorsal horn was found to correlate with IL-1beta secretion following both LPS and ATP. In behavioral studies, intrathecal injection of LPS in the lumbar spinal cord produced mechanical hyperalgesia in rat hindpaws, which was attenuated by concomitant injections of either a nonspecific (oxidized ATP) or a specific (A-438079) P2X7 antagonist. In addition, LPS-induced hypersensitivity was observed in wild-type but not P2X7 knock-out mice. These data suggest a critical role for the P2X7 receptor in the enhanced nociceptive transmission associated with microglial activation and secretion of IL-1beta in the dorsal horn. We suggest that CNS-penetrant P2X7 receptor antagonists, by targeting microglia in pain-enhanced response states, may be beneficial for the treatment of persistent pain.


Subject(s)
Hyperalgesia/metabolism , Interleukin-1beta/metabolism , Receptors, Purinergic P2/metabolism , Spinal Cord/metabolism , Adenosine Triphosphate/analogs & derivatives , Adenosine Triphosphate/pharmacology , Analysis of Variance , Animals , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay/methods , Female , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , Glial Fibrillary Acidic Protein/metabolism , Hyperalgesia/chemically induced , In Vitro Techniques , Lipopolysaccharides/pharmacology , Male , Mice , Mice, Knockout , Microglia/drug effects , Microglia/metabolism , Mitogen-Activated Protein Kinase 13/metabolism , Pain Measurement , Pain Threshold/drug effects , Phosphopyruvate Hydratase/metabolism , Purinergic P2 Receptor Agonists , Purinergic P2 Receptor Antagonists , Pyridines/pharmacology , Rats , Rats, Wistar , Receptors, Purinergic P2/deficiency , Receptors, Purinergic P2X7 , Spinal Cord/anatomy & histology , Spinal Cord/cytology , Spinal Cord/drug effects , Tetrazoles/pharmacology , Theophylline/analogs & derivatives , Theophylline/pharmacology , Time Factors
5.
Eur J Pain ; 13(6): 554-63, 2009 Jul.
Article in English | MEDLINE | ID: mdl-18801682

ABSTRACT

Extracellular acidification is a component of the inflammatory process and may be a factor driving the pain accompanying it. Acid-sensing ion channels (ASICs) are neuronal proton sensors and evidence suggests they are involved in signalling inflammatory pain. The aims of this study were to (1) clarify the role of ASICs in nociception and (2) confirm their involvement in inflammatory pain and determine whether this was subunit specific. This was achieved by (1) direct comparison of the sensitivity of ASIC1, ASIC2, ASIC3 and TRPV1 knockout mice versus wildtype littermates to acute thermal and mechanical noxious stimuli and (2) studying the behavioural responses of each transgenic strain to hind paw inflammation with either complete Freund's adjuvant (CFA) or formalin. Naïve ASIC1(-/-) and ASIC2(-/-) mice responded normally to acute noxious stimuli, whereas ASIC3(-/-) mice were hypersensitive to high intensity thermal stimuli. CFA injection decreased mechanical and thermal withdrawal thresholds for up to 8 days. ASIC2(-/-) mice had increased mechanical sensitivity on day 1 post-CFA compared to wildtype controls. TRPV1(-/-) mice had significantly reduced thermal, but not mechanical, hyperalgesia on all days after inflammation. Following formalin injection, ASIC1(-/-) and ASIC2(-/-), but not ASIC3(-/-) or TRPV1(-/-), mice showed enhanced pain behaviour, predominantly in the second phase of the test. These data suggest that whilst ASICs may play a role in mediating inflammatory pain, this role is likely to be modulatory and strongly dependent on channel subtype.


Subject(s)
Formaldehyde , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/physiology , Pain Measurement , Pain/genetics , Pain/psychology , Sodium Channels/genetics , Sodium Channels/physiology , Acid Sensing Ion Channels , Animals , Behavior, Animal , Freund's Adjuvant , Hot Temperature , Hyperalgesia/chemically induced , Hyperalgesia/physiopathology , Male , Mice , Mice, Knockout , Pain/physiopathology , Pain Threshold/physiology , RNA/biosynthesis , RNA/genetics , TRPV Cation Channels/genetics , TRPV Cation Channels/physiology
6.
Proc Natl Acad Sci U S A ; 104(25): 10655-60, 2007 Jun 19.
Article in English | MEDLINE | ID: mdl-17551020

ABSTRACT

A recent major conceptual advance has been the recognition of the importance of immune system-neuronal interactions in the modulation of brain function, one example of which is spinal pain processing in neuropathic states. Here, we report that in peripheral nerve-injured rats, the lysosomal cysteine protease cathepsin S (CatS) is critical for the maintenance of neuropathic pain and spinal microglia activation. After injury, CatS was exclusively expressed by activated microglia in the ipsilateral dorsal horn, where expression peaked at day 7, remaining high on day 14. Intrathecal delivery of an irreversible CatS inhibitor, morpholinurea-leucine-homophenylalanine-vinyl phenyl sulfone (LHVS), was antihyperalgesic and antiallodynic in neuropathic rats and attenuated spinal microglia activation. Consistent with a pronociceptive role of endogenous CatS, spinal intrathecal delivery of rat recombinant CatS (rrCatS) induced hyperalgesia and allodynia in naïve rats and activated p38 mitogen-activated protein kinase (MAPK) in spinal cord microglia. A bioinformatics approach revealed that the transmembrane chemokine fractalkine (FKN) is a potential substrate for CatS cleavage. We show that rrCatS incubation reduced the levels of cell-associated FKN in cultured sensory neurons and that a neutralizing antibody against FKN prevented both FKN- and CatS-induced allodynia, hyperalgesia, and p38 MAPK activation. Furthermore, rrCatS induced allodynia in wild-type but not CX3CR1-knockout mice. We suggest that under conditions of increased nociception, microglial CatS is responsible for the liberation of neuronal FKN, which stimulates p38 MAPK phosphorylation in microglia, thereby activating neurons via the release of pronociceptive mediators.


Subject(s)
Cathepsins/antagonists & inhibitors , Microglia/enzymology , Pain/drug therapy , Pain/etiology , Spinal Cord/enzymology , Animals , Cathepsins/genetics , Dose-Response Relationship, Drug , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/pharmacology , Injections, Spinal , Ligation , Male , Mice , Mice, Inbred C57BL , Pain Measurement , Rats , Rats, Wistar , Recombinant Proteins/antagonists & inhibitors , Sciatic Nerve/injuries , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...